title: Thermochemotherapy in vivo of a C3H mouse mammary carcinoma: single fraction heat and drug treatment.
abstract: The interaction between water bath hyperthermia (43.5 degrees C) and six cancer chemotherapeutic agents in vivo was studied in a transplantable C3H mouse mammary carcinoma grown s.c. in the feet of C3D2F1/Bom mice. Due to differences in tumour regrowth rate between treatment groups, both tumour growth time (TGT) and specific growth delay (SGD) were used as effect parameters. The largest tumour response was observed when the drug was given 15 min prior to heat--this timing was used for dose-effect experiments. Enhancement ratios were the ratios of slopes of dose-effect curves subjected to linear regression analysis. The drug enhancement ratio (DER) was not significantly larger than 1.0 for LD 1% of adriamycin, 5-fluorouracil, methotrexate and vincristine. For cyclophosphamide (CTX) and mitomycin C (MMC) both DER and TER (thermal enhancement ratio) were significantly larger than 1.0. The TGT ratios (SGD ratios in parentheses) were: DER (LD 1%): CTX 1.4 +/- 0.1 (2.1 +/- 0.1), MMC 1.3 +/- 0.1 (1.4 +/- 0.1); TER (43.5 degrees C 30 min): CTX 1.6 +/- 0.1 (2.7 +/- 0.2), MMC 2.8 +/- 0.5 (3.3 +/- 0.7). The data support the choice of CTX and MMC in preference to the other drugs investigated for clinical thermochemotherapy studies.
authors.affiliation: Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
authors.forename: O R
authors.initials: OR
authors.lastname: Monge
authors.forename: E K
authors.initials: EK
authors.lastname: Rofstad
authors.forename: O
authors.initials: O
authors.lastname: Kaalhus
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006979:Hyperthermia, Induced; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008809:Mice, Inbred C3H; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate